A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand
暂无分享,去创建一个
S. Lewin | K. Ruxrungtham | D. Cooper | G. Dore | J. Amin | J. Sasadeusz | S. Bowden | A. Avihingsanon | R. Rerknimitr | G. Matthews | P. Marks | S. Locarnini | Panusit Petcharapirat
[1] Y. Benhamou. Hepatitis B in the HIV-Coinfected Patient , 2007, Journal of acquired immune deficiency syndromes.
[2] S. Locarnini,et al. SeqHepB: a sequence analysis program and relational database system for chronic hepatitis B. , 2007, Antiviral research.
[3] George Kitis,et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. , 2006, Gastroenterology.
[4] V. Johnson,et al. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127 , 2006, Hepatology.
[5] R. Bruno,et al. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection , 2006, AIDS.
[6] A. Theamboonlers,et al. Hepatitis B seroprevalence in Thailand: 12 years after hepatitis B vaccine integration into the national expanded programme on immunization , 2006, Tropical medicine & international health : TM & IH.
[7] S. Lewin,et al. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy , 2006, AIDS.
[8] C. Katlama,et al. Anti‐hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV‐infected patients , 2006, Hepatology.
[9] E. Wilkins,et al. BHIVA guidelines on HIV and chronic hepatitis: coinfection with HIV and hepatitis B virus infection (2005) , 2005, HIV medicine.
[10] Thomas Berg,et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. , 2005, The New England journal of medicine.
[11] P. Morlat,et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. , 2005, Journal of hepatology.
[12] A. Mocroft,et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort , 2005, AIDS.
[13] G. Gerken,et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial , 2005, The Lancet.
[14] R. Bruno,et al. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome , 2004, AIDS.
[15] A. Vibhagool,et al. Prevalence of hepatitis B virus and hepatitis C virus co-infection with human immunodeficiency virus in Thai patients: a tertiary-care-based study. , 2004, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.
[16] P. Price,et al. Immune restoration disease after antiretroviral therapy , 2004, AIDS.
[17] J. Sasadeusz,et al. Immune reconstitution hepatitis in HIV and hepatitis B coinfection, despite lamivudine therapy as part of HAART. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] K. Ruxrungtham,et al. Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort , 2004, AIDS.
[19] D. Cooper,et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. , 2004, The Journal of infectious diseases.
[20] V. Soriano,et al. Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine. , 2002, AIDS.
[21] B. Gazzard,et al. An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals , 2003, AIDS.
[22] J. Phair,et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS) , 2002, The Lancet.
[23] V. Soriano,et al. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. , 2002, AIDS.
[24] H. Kumada,et al. [Chronic hepatitis B]. , 2001, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology.
[25] R. Chaisson,et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. , 2000, JAMA.
[26] D. Cooper,et al. Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. , 1999, The Journal of infectious diseases.
[27] P. Tangkijvanich,et al. Genotypes and subtypes of hepatitis B virus in Thailand. , 1998, The Southeast Asian journal of tropical medicine and public health.
[28] A. Bertoletti,et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. , 1998, The Journal of clinical investigation.
[29] J. J. Henning,et al. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.
[30] J. Stockman,et al. A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B , 2007 .
[31] J. Stockman,et al. Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B , 2007 .
[32] S. Locarnini,et al. HBV genotyping and analysis for unique mutations. , 2004, Methods in molecular medicine.